Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH)‘s stock had its “overweight” rating reissued by equities research analysts at Piper Jaffray Cos. in a report released on Wednesday. They presently have a $23.00 price objective on the stock, up from their prior price objective of $22.00. Piper Jaffray Cos.‘s price target indicates a potential upside of 21.63% from the stock’s previous close.
Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) opened at 18.85 on Wednesday. Amphastar Pharmaceuticals has a one year low of $10.50 and a one year high of $21.16. The stock has a 50 day moving average of $17.96 and a 200-day moving average of $14.80. The company has a market capitalization of $850.53 million and a PE ratio of 61.20.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its earnings results on Monday, August 8th. The company reported $0.23 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.22. The firm had revenue of $68 million for the quarter, compared to the consensus estimate of $62.10 million. During the same period in the prior year, the business earned ($0.09) EPS. Amphastar Pharmaceuticals’s quarterly revenue was up 26.4% on a year-over-year basis. On average, equities analysts forecast that Amphastar Pharmaceuticals will post $0.37 earnings per share for the current fiscal year.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/07/amphastar-pharmaceuticals-amph-overweight-rating-reiterated-at-piper-jaffray-cos.html
Several hedge funds and institutional investors have modified their holdings of AMPH. Millennium Management LLC boosted its position in shares of Amphastar Pharmaceuticals by 146.2% in the fourth quarter. Millennium Management LLC now owns 137,949 shares of the company’s stock worth $1,963,000 after buying an additional 81,912 shares in the last quarter. Gupta Wealth Management LLC boosted its position in shares of Amphastar Pharmaceuticals by 33.3% in the fourth quarter. Gupta Wealth Management LLC now owns 100,000 shares of the company’s stock worth $1,423,000 after buying an additional 25,000 shares in the last quarter. Acadian Asset Management LLC boosted its position in shares of Amphastar Pharmaceuticals by 43.4% in the first quarter. Acadian Asset Management LLC now owns 452,371 shares of the company’s stock worth $5,428,000 after buying an additional 136,816 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. acquired a new position in shares of Amphastar Pharmaceuticals during the first quarter worth about $180,000. Finally, Teachers Advisors Inc. boosted its position in shares of Amphastar Pharmaceuticals by 18.8% in the first quarter. Teachers Advisors Inc. now owns 492,136 shares of the company’s stock worth $5,906,000 after buying an additional 77,910 shares in the last quarter.
AMPH has been the subject of a number of other research reports. Needham & Company LLC lowered their target price on shares of Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “buy” rating for the company in a research note on Tuesday, May 10th. Zacks Investment Research downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, July 28th. BMO Capital Markets initiated coverage on shares of Amphastar Pharmaceuticals in a research note on Tuesday, June 28th. They set a “market perform” rating and a $17.00 target price for the company. Finally, Jefferies Group lifted their target price on shares of Amphastar Pharmaceuticals from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Tuesday, August 9th. Two investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $20.00.
In other news, CFO William J. Peters sold 2,297 shares of Amphastar Pharmaceuticals stock in a transaction dated Monday, July 18th. The shares were sold at an average price of $17.76, for a total transaction of $40,794.72. Following the completion of the transaction, the chief financial officer now directly owns 64,652 shares in the company, valued at $1,148,219.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Jason B. Shandell sold 10,000 shares of Amphastar Pharmaceuticals stock in a transaction dated Monday, August 22nd. The shares were sold at an average price of $19.95, for a total transaction of $199,500.00. Following the transaction, the general counsel now owns 212,961 shares of the company’s stock, valued at $4,248,571.95. The disclosure for this sale can be found here.
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.